Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JT, I don't agree with that logic at all. Typically when big pharma partners with a smaller company big pharma runs the clinical trials all the small company does it provide the drug...perhaps hence the Evonik deal.
In response to:
Jewel think about it. Why would he cut a deal for distribution if he has BP waiting in the wings. BP has their own distribution companies. His decision tells me that he is ready to go it alone if no deal can be made with BP. Then it is onto more dilution.imo
Leo no more Aspire sales that last one almost wiped out your company. You should have enough cash now to hold out for a deal! No new spending! Take the deal on B-OM or B-UP you are never going to get what you think you should get...take whats offered!
Prurisol is you wildcard. Press the CRO to release the results..good or bad get it out to the publicn ASAP. Wondering why there is no results is in some ways worse than bad results.
Been invested in this company for over 10 years. Inflection point is upon you! Get it done!
I say don't be a retail schmuck! Good time to buy..
Hello JPsooner, partnership sure is a possibility but why wind down all the clinical trials just to partner one or partner one drug in one indication? With a 70 million market cap. and limited funding especially for phase 3 trials, what would be the motivation for big pharma to partner with Innovation when it would make a whole lot more sense for them to acquire the whole portfolio?
Now that I think about I don't believe the company has given any guidance on any future trials for their drugs. Sure its perhaps its too early for B-OM and Prurisol but what about Kevetrin, B-UP/UC and B ABX.
Given their age and stock holding in the company I don't see Dr. Menon and Leo riding any of these drugs through a phase 3 and a big meeting with the FDA, partner or not. And they cannot really sell their stock in the company until the company is no more.
I have been invested in the is company for 11 years and something is clearly different now. For my own personal investment decisions they need to partner or sell with in ~6 months...
And all of that is IMO
Hello waikikian, I would not expect a crazy buyout number. A company with a market cap. of 75 million will not be bought out for 30 billion or even 10 billion overnight. A lot of it depends on what the FDA has to say about B-OM and moreover the Prurisol results especially given that trial will be the first trial designed for statistical relevance.
My guesses: Middle of the road...1-2 billion
If Prurisol results are strong ~5 billion
Looks like the company is wrapping things up for a buyout/sale. Drug trials are coming to an end. Only thing left is assessing the value of the portfolio.
Kevetrin
Kevetrin phase 2a went only far enough to show Kevetrin modulating p53 as big pharma requested and stopped abruptly. Exploring feasibility of oral tablet -value option.
Brilacidin
ABX small company sees no way ahead on their own with two large and expensive phase 3 trials.
IBD: the secretive trial.
OM: Buyer needs to hear what the FDA has to say here.
Prurisol: waiting for results.
We have no active clinical trials right now https://clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search
Ever since Brilacidin the company always has several active trials running at the same time.
Dr. Menon appears to be going in to retirement and Leo may want to start 8K'ing all his remaining PR's.
We lost our floor at 0.64 cents because some investors realized after prurisol results and with no other ongoing trials there will be no catalyst moving forward nothing to keep the company afloat. I think they are going to sell the company so it does not matter.
We are assessing value and wrapping up for a sale---IMO
Probably the clay traders on this run
Wow, that Biocentury presentation is sharp it makes our current market cap. seemingly too hard to believe but I do believe this will be changing in the coming months.
Looks like Leo's investors roadshow is paying off. I will have to start checking institional holdings in the coming months.
So he brought in a psorasis expert to deal with the FDA for a antibiotoc?
We are in trouble
I think he contacted Dr. Trust in this regard.
Management believed the dismissal of Rosen suit would lead to a rebound in share price making Aspire financing work for funding B ABX. When that didn't pan out they delayed the start and informed shareholders. I don't see any issues here althouth disappointing I would prefer they didn't dilute at these levels for that much funding -25 million through Aspire.
Current plan appears to be wrapping up B-om and B-up to present a complete B-package for partnership...IMO
Aspire does seem to cater to the small cap. low volume companies a scenario that would allow a fair amount of price control on a company's stock. But what else can they do?
The obvious one is to partner but that does not appear to fair well with the company that is trying to "maximize shareholder value"? Hard to believe that no one is interested in partnering with B phase3 ABX but apparently the deal is not to companies liking? I say take the partnership even if the deal is not top dollar. AE's are still a concern heading in to p3 top money will not be there going in. The company has much more to offer. Give the discount Pfizer in a partnership not Aspire.
Warrants -yuck
The shelf----I wish! We would be like all the other young biotechs but we don't nearly have the demand to do so.
My favorite would be selling the Baker Brothers 50 million share at $1.25 and get one of them on the BoD.
Financing is the biggest issue for the company right now (imo) hopefully our new President has more than just experience in clinical trials.
Hopefully a sign of Dr.B's influence om the company, outside logic. Or perhaps Leo read somewhere that no company ever directly uplisted from the pinks to the NASDAQ.
We should have never dropped down to the pinks in the first place. Nice development.
The likely problem is not finding a partner its finding the best terms of any deal to be made. If offers have been made they may not be to the companies liking so you issue a PR (todays). Showing your willing to move ahead without one.
The Prurisol results were impressive I am sure there are interested parties but not at the terms the company care for. Their cash position probably does not help here.
CTIX is the opposite of almost any of their peers they have several promising drugs.
Wow! Excellent move
Yes I have. OM trials take a long time the exclusion criteria is so steep.
NR, i think its easy to say that B ABX will not hit the timeline with co. going back to the FDA for protocol approval. K ovarion is last one up for me in the first half of the year.
Well nose-breathing after the first few miles is impressive. The secrecy is intriguing. Any countries with a serious U.P. problem?
Where's Waldo? I mean B-UP?
Liked today's PR. B-UP started no buildup.
We need the "People's Court!" Da dun dun da
Darn unsettled funds, with no PR yet its like having insider information but not being able to act on it. Must be frustrating.
MXA this is one of these buy and sell events. Not sure why you would be against a PR. You might be able to make a nickel or better on each share!
Cabel, I have same thought as you with P it was better then expected perhaps we can go it alone (again)?
I am with you Mr. the NR. Another way to have/keep money on the balance sheet is to control spending. I do not know about you but I was disappointed to hear the company wanted to start the B-UP trial. Then a few weeks ago they PR'd reactivating another B-XXX protocol with FDA. I don't see these developments as positive given our cash position, especially given that they will have to leverage everything to get B-ABSSSI through its 2 phase 3's.
Positive trial results do not move this company forward. Sadly, I believe if the B-OM trial results were announced tomorrow and the results were fantastic we would not see a significant gain in stock price, dangerous thoughts for a very long-time investor here.
The company needs to work on the other side of the equation here and show investors they have the ability to bring these drugs to market (by any means). To do so, I believe they will have to go outside of their comfort zone and cede some control to others (partners, truly independent BOD members etc). Start thinking outside their secure box!
IMO
Thanks Karin but this problem has stretched back a few years now. Simply talking about it does not help much like all the talk with uplisting that eventually lead to a "sucker punch" from Mako leading to our current market cap. Talking partners for so long and not obtaining one will only lead to more hit pieces. The company could have partnered B ABSSSI nearly two years ago and the company would be in much better conition on all fronts.
Great trial results are not pushing us forward they are trumped by a lack of non-dilutive financing and the expertise needed to go to the next level. Hopefully, the company can go forward without talk of partnering until they actually have one and they realize that just announcing great trial results is sufficient...work on the other side of the equation. IMO
Best SA article I ever read! Finally someone noting that following the science and trial results is only half the battle and Cellceutix in my view is completely losing the other half in expertise and financing.
The company relies too much on moving forward with Aspire and their shelf registry. Now with 3 potential blockbuster how are you going to pay for it all? At this point simply announcing new trials like B-UP only exasperates their financial conditions or those investors that worry about such, down ~5 million on the last 10Q. The market has the stock locked in under $2 and the only current forward path is dilute, dilute at these prices.
I like Cellceutix management team but the only clinical trial experience they have is at this particular company and the road forward with the FDA does not get easier. They have been adding some experience in to the mix, Dr. Trust etc for Brilacidin phase 3 but they need to add across the board.
Getting an experienced partner with Brilacidin, Kevetrin or Prurisol is much needed at this point and none of these drugs should be off the negotiation table. Polymed failed with a great antibiotic drug a lot of arrogance and no funds!
I can see the forest for the trees and it not a matter of patience anymore. Just announcing great trial results is not enough -GET A PARTNER gain financing and experience..Cellceutix -GET OUT OF THE BOX you put yourself in!
IMO =-)
From todays PR "by taking Kevetrin from the acedemic setting" did Leo just take a shot at DF Harvard for their slow pace on K p1?
Thanks..odd that he attached a date to it, hopefully it comes to fruitition.
Thanks Cabel, was it a private conversation or announced at the shareholder meeting?
What PR tells us that they are planning on adding another board member? I keep seeing this mentioned and I don't know why? Is it just hopeful wishing with a new member coming from a partnership or financing deal?
Wild Card Prurisol comes through. When the company switched from testing Prurisol from moderate to severe psoriasis to mild to moderate it might been better to switch the scoring system as well. With the IGA scale in mild to moderate cases Prurisol would have had to nearly clear all of the psoriasis in a short-time period. Another Monday quarterback comment comes with using the 50 and 100 mg at all.
Looking forward to data on the time-scale on this trial to see what role duration plays with clearing psoriasis at the 200 dose level. Really just hoping this is enough to get a partner for Prurisol so we can get trucking with Kevetrin and Brilacidin.
I like the no-news its been driving the stock up for the last month.
Adam Feuerstein is a notorious short of small biotechs. I would only worry if he said something positive about CTIX. I would more concerned if you had a monkey jumping up and down on youtube holding a "CTIX sucks" poster.
FDA asking for changes made in a SPA is not a rejection rather a step towards acceptance. It was not buried it was the whole second half of the PR. Please note also that we were PR'd when the phase 2b Brilacidin data went in to "soft lock" too.
Sounds like someone sold on Friday?
Kevetrin data about to be published?
Was Kevetrin listed as ODD for Pancreatic cancer before, I don't recall a PR on that one? https://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm
We need to get Kevetrin data published.
What?....Who?....Yeah!